Free Trial
→ Market down? Do this now. (From Colonial Metals) (Ad)

uniQure 11/5/2024 Earnings Report

uniQure logo
$12.84 -0.12 (-0.93%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

uniQure EPS Results

Actual EPS
-$0.91
Consensus EPS
-$1.12
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

uniQure Revenue Results

Actual Revenue
$2.29 million
Expected Revenue
$2.73 million
Beat/Miss
Missed by -$440.00 thousand
YoY Revenue Growth
N/A

uniQure Announcement Details

Quarter
Date
11/5/2024
Time
Before Market Opens

Conference Call Resources

uniQure Earnings Headlines

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
February 7, 2025 | benzinga.com
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
February 7, 2025 | prnewswire.com
Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
February 22, 2025 | Colonial Metals (Ad)
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
February 3, 2025 | globenewswire.com
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
January 30, 2025 | globenewswire.com
uniQure Announces Pricing of its Public Offering
January 8, 2025 | globenewswire.com
See More uniQure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email.

About uniQure

uniQure (NASDAQ:QURE) N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

View uniQure Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles